ClinicalTrials.gg
RecruitingNCT07393152ASD OutcomeUpdated Feb 20, 2026

Pilot Study on Collaborative, Comprehensive, Multidimensional and Quality of Life Tools for Priority Definition, Shared Decision Making, Outcome Evaluation and Quality of Care Improvement in ASD Individuals and Programs in the Real World.

An observational study in Autism Spectrum Disorders, sponsored by Antonella Costantino. Recruiting at 3 sites in Italy. Open to participants aged 0 Years to 11 Years. Per ClinicalTrials.gov, last updated 2026-02-20.

Sponsored by Antonella Costantino · Observational

How we know

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
400
Ages
0 Years to 11 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 90 studies in Autism Spectrum Disorder with a site in Italy — 48 open to participants now, 55 under way, 1 of them phase 3. Autism Spectrum Disorder · Italy.

Planned enrollment
2nd of 27
400 · median 100
Started
2025
with 5 others
Observational
27 of 90
17 open now
Primary completion
2026-10
later than 41 of 54 live
Registered
76th of 90
by date

Among the 90 studies in Autism Spectrum Disorder with a site in Italy, this one is the 2nd largest by planned enrollment of the 27 observational ones that give a count, is one of 6 that started in 2025, is one of 27 observational ones, reaches primary completion later than 41 of the 54 other live ones, and was the 76th registered.

Autism Spectrum Disorder

1,733 studies on the registry are indexed under Autism Spectrum Disorder; 503 are open to participants now.

Browse Autism Spectrum Disorder studies →

Open to participants now

48 of the 90 studies in Autism Spectrum Disorder with a site in Italy are open now. Recruiting first, the newest first:

42 more — sign in →

All 48 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 351 Autism Spectrum Disorder studies recruiting now, 48 (14%) set no upper age limit and 296 (84%) stop at 75 or younger; 301 take children under 18; 92 take healthy volunteers.

This study: 0 Years to 11 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 90 studies in Autism Spectrum Disorder with a site in Italy, or all of them as a file.
02

Study summary

ASD is a very complex and lifelong disorder. Patients' functioning is influenced by multiple factors, including treatments, inclusion and life contexts. Nonetheless, outcome measures are still point-specific and highly fragmented, rarely considering global or multidimensional functioning, development or long-term modifications, especially in the real world. The present study considers ongoing real-life treatments in three different NHS settings, in line with the Italian Guidelines. Two age classes will be considered, 0-5 and 6-11, adding new outcome tools pre-post intervention to those already used, to evaluate quality of life, global functioning, multidimensional needs and strengths and shared decision making. Correlations between the different outcome tools will be explored, and possible clusters will be investigated. Acceptability of the outcome tools for the operators, patients and families, as well as usefulness and sustainability in daily practice, will also be evaluated.

03

Conditions studied

  • Autism Spectrum Disorders

Keywords

  • Global functioning
  • Quality of life
  • Child and adolescent need and strenght
  • autism spectrum disorders
  • Outcome evaluation tools
04

Who can participate

Ages eligible
0 Years to 11 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Children diagnosed with ASD enrolled in one of the intervention programs in line with the national guidelines, within the partner institutions or other NPIA/rehabilitation services for developmental age of the Lombardy Region are eligible. The overall expected sample is 400 male and female children, under 12 years of age, 200 children aged 0-5 years at T0 and 200 children aged 6-11 years at T0.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ASD diagnosis according to the criteria shared by the regional NFA network
  • Age under 12
  • Consent from the person holding parental responsibility for health choices

Exclusion criteria

Exclusion Criteria:

  • Subjects aged 12 years or older at the time of enrollment
  • No consent from the person holding parental responsibility for health choices
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
400 participants (estimated)
Target follow-up
12 Months
Patient registry
Yes

Groups and cohorts

  • Children aged 0-11 with ASD diagnosis

    Patients will be enrolled in ongoing treatments in the real context as long as they are in line with the national guidelines for autism, in at least three different national health facilities (SSN) in Lombardy, to represent the variability of the possible organizations of services and interventions, adding new outcome tools.

    Other: DD-CGAS (Wagner et al. 2007) · Other: Pediatric Quality of Life Inventory (PedsQL). · Other: Child and Adolescent Needs and Strengths (CANS) (Lyons 2022)

Interventions

  • OtherDD-CGAS (Wagner et al. 2007)

    The DD-CGAS is a clinician-completed scale that provides a global rating of the child's functioning. The score refers to the subject's typical functioning during a specified period of time, usually the week prior to the assessment. It is a global assessment based on all available sources of information and all domains of functioning, including self-sufficiency, communication, social behavior, and academic/school functioning. The score should not be influenced by the specific diagnosis, the perceived cause of dysfunction (e.g., cognitive or physical limitation, environmental constraints, behavioral disturbance), or the type and severity of symptoms. The DD-CGAS is a dimensional scale with scores ranging from 1 to 100, with 1 representing the greatest impairment in functioning and 100 representing the best functioning. Each decile (e.g., 1-10, 11-20) has a specific description. The instrument has excellent replicability between raters and temporal stability.

  • OtherPediatric Quality of Life Inventory (PedsQL).

    The PedsQL is designed for children and adolescents between the ages of 2 and 18 years and takes approximately 5 minutes to complete. It is administered as a self-report instrument or via proxy interview. The proxy interview version corresponds to the age of the child (e.g., 2-4 years, 5-7 years, 8-12 years, and 13-18 years). The PedsQL consists of 23 items that assess 4 broad scales, including: physical functioning, emotional functioning, social functioning, and academic functioning. Items are rated using a 5-point Likert scale (0 = never; 4 = almost always), with the total score calculated as the sum of all items considered. PedsQL item scores are inverted and linearly transformed to a 0 to 100 scale, with higher scores indicating a better perception of health-related quality of life. It is important to note that the PedsQL has been validated in children with autism, including parents of children with autism (Vasilopoulou et al. 2016; Perry, N. et al. 2024).

  • OtherChild and Adolescent Needs and Strengths (CANS) (Lyons 2022)

    The Child and Adolescent Needs and Strengths scale (CANS) (Lyons 2022) is an open source tool widely used to assess the needs and strengths of children, adolescents, and their families, in clinical, educational and social services settings. It is organized into multiple domains that cover various aspects of a child's life. Common domains include life functioning, behavioral/emotional needs, risk behaviors, strengths, caregiver needs and strengths. Additional modules as trauma can be used.The tool uses a scoring system that reflects the level of need or strength in each area. Typically, needs are rated on a scale from 0 to 3, where 0: No evidence of problems; 1: Watchful waiting, preventive action needed; 2: Action or intervention is required; 3: Immediate or intensive action required. Strengths are rated similarly, with higher scores reflecting greater need for action to support the development of each specific strength.

06

What researchers measure

Primary outcomes

  1. Specific clusters of CANS items that differentiate the profiles of needs and strengths of users at T0.

    The primary objective of the study is to identify specific clusters of CANS items that differentiate the profiles of needs and strengths of users at T0.

    Time frame: From March 2025 to August 2026

Secondary outcomes

  1. Correlations between CANS assessment and participants' global functioning (DD-CGAS)

    The outcome measure TAI measured with CANS and expressed as the sum of the actionable items (see section "Groups and Intervention") will be correlated will be correlated with outcome measure quality of life, measured with DD-CGAS expressed as 1-100 score con 1 che rappresenta la maggiore compromissione del funzionamento e 100 il miglior funzionamento

    Time frame: From March 2025 to August 2026

  2. Correlations between CANS assessment and participants' quality of life (PEDSQL)

    The outcome measure TAI measured with CANS and expressed as the sum of the actionable items (see section "Groups and Intervention") will be correlated will be correlated with outcome measure quality of life, measured with DD-CGAS expressed as 0-100 score with higher scores on the PedsQL indicating better perceptions of health-related quality of life.

    Time frame: From March 2025 to August 2026

  3. Evaluation of changes in children's needs over time based on CANS actionable items.

    Differences between T0 and T1 TAI measeured with CANS and expressed as the sum of the actionable items (see section "Groups and Interventions") will be evaluated using a paired sample t test.

    Time frame: march 2025 to august 2026

  4. Evaluation of changes in children's Quality of Life over time.

    Differences between T0 and T1 PedsQL scores (range 0-100, where 0 represents the lowest quality of life and 100 represents the highest quality of life ) will be evaluated using a paired sample t test.

    Time frame: from march 2025 to august 2026

  5. Evaluation of changes in children's global functioning

    DESCRIPTION Differences between T0 and T1 DD-CGAS scores (range 1-100, where 1 represents the lowest level of global functioning and 100 represents the highest level of global functioning) will be evaluated using a paired sample t test.

    Time frame: from march 2025 to august 2026

07

Study locations

3 of 3 sites recruiting
  • IRCCS Eugenio Medea- U.O. di Neuropsichiatria infantile - Disturbi del Neurosviluppo
    Bosisio Parini, (LC) 23842, Italy
    Recruiting
  • UOSD Disturbo Autistico nel ciclo della vita
    Busto Arsizio, (VA) 21052, Italy
    Recruiting
  • SC Child and Adolescence Neuropsychiatric Unit, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico , Milan, Italy
    Milan, Michigan 20122, Italy
    Recruiting
08

References and documents

Publications

  • Sandbank M, Pustejovsky JE, Bottema-Beutel K, Caldwell N, Feldman JI, Crowley LaPoint S, Woynaroski T. Determining Associations Between Intervention Amount and Outcomes for Young Autistic Children: A Meta-Analysis. JAMA Pediatr. 2024 Aug 1;178(8):763-773. doi: 10.1001/jamapediatrics.2024.1832. PubMed 38913359 ↗
  • Provenzani U, Fusar-Poli L, Brondino N, Damiani S, Vercesi M, Meyer N, Rocchetti M, Politi P. What are we targeting when we treat autism spectrum disorder? A systematic review of 406 clinical trials. Autism. 2020 Feb;24(2):274-284. doi: 10.1177/1362361319854641. Epub 2019 Jul 3. PubMed 31269800 ↗
  • Perry N, Boulton KA, Hodge A, Ong N, Phillips N, Howard K, Raghunandan R, Silove N, Guastella AJ. A psychometric investigation of health-related quality of life measures for paediatric neurodevelopment assessment: Reliability and concurrent validity of the PEDS-QL, CHU-9D, and the EQ-5D-Y. Autism Res. 2024 May;17(5):972-988. doi: 10.1002/aur.3127. Epub 2024 Apr 10. PubMed 38597587 ↗
  • Ne'eman A. When Disability Is Defined by Behavior, Outcome Measures Should Not Promote "Passing". AMA J Ethics. 2021 Jul 1;23(7):E569-575. doi: 10.1001/amajethics.2021.569. PubMed 34351268 ↗
  • Jolliffe, I. T. (2002). Principal Component Analysis (2nd ed.). Springer.
  • Godoy PBG, Sumiya FM, Seda L, Shephard E. A systematic review of observational, naturalistic, and neurophysiological outcome measures of nonpharmacological interventions for autism. Braz J Psychiatry. 2022 Nov 5;44(5):532-547. doi: 10.47626/1516-4446-2021-2222. Epub 2022 Jun 24. PubMed 35751600 ↗
  • Cordell, K. D. et al. (2016). Patterns and priorities of service need identified through the Child and Adolescent Needs and Strengths (CANS) assessment. Children and Youth Services Review, 60, 129-135.
  • Brown, C. C., Wang, E. W., & Goad, C. (2022). A review of the psychometric properties of the child and adolescent needs and strengths (CANS): Perspectives on the present state of the literature and future directions. Residential Treatment for Children & Youth, 39(3), 331-346.
  • Benzoni, S. et al. (2020). Partecipazione e valutazione di esito nella salute mentale in età evolutiva: gli strumenti della famiglia CANS nell'esperienza italiana. Erickson
  • Babamoradi H, van den Berg F, Rinnan A. Confidence limits for contribution plots in multivariate statistical process control using bootstrap estimates. Anal Chim Acta. 2016 Feb 18;908:75-84. doi: 10.1016/j.aca.2016.01.002. Epub 2016 Jan 7. PubMed 26826689 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Oct 2026, 19 months after the start.

Of 98 non-industry observational studies under Autism Spectrum Disorder, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 120. This study's planned 19 months is below that.

Counting every sponsor, half of 112 studies reached it within 40 months; a quarter within 26 and three quarters within 120.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 30, 2025
First posted
Feb 6, 2026
StartActual
Mar 13, 2025
Primary completionEst.
Oct 31, 2026
CompletionEst.
Oct 31, 2026
Last update
Feb 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07393152
Lead sponsor
Antonella Costantino
Collaborators
IRCCS Eugenio Medea, Azienda Socio Sanitaria Territoriale della Valle Olona
Responsible party
Antonella Costantino (Director Child and Adolescence Neuropsychiatric Unit, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico , Milan, Italy, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico) — Sponsor-investigator
First posted
Feb 6, 2026
Start date
Mar 13, 2025
Primary completion
Oct 31, 2026 (estimated)
Completion
Oct 31, 2026 (estimated)
Last update
Feb 20, 2026

Study contacts

Maria Antonella Costantino
Contact
antonella.costantino@policlinico.mi.it
+39 02 5503.4400

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion